Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

July 31, 2016

Study Completion Date

July 31, 2017

Conditions

Multiple Myeloma

Interventions

DRUG

Amrubicin

40, 60, or 80 mg/m2 intravenous (IV)

DRUG

Lenalidomide

15 mg daily by mouth

DRUG

Dexamethasone

40 mg weekly by mouth

DRUG

Aspirin

81 or 325 mg daily by mouth

DRUG

Pegfilgrastim

6 mg subcutaneous on Day 2

Trial Locations (1)

Stanford University School of Medicine, Stanford